Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of ...

Piramal Pharma Solutions invests $80 million in Lexington facility expansion to meet growing demand in injectables market.

Piramal's global Contract Development and Manufacturing Organization plans to more than double the facility’s capacity by Q1 ...

The investment has been financed through bank loans and internal accruals, and aims to enhance site’s capacity to meet rising ...

Piramal Pharma Solutions Inc. today announced plans to expand its current Lexington operations with a nearly $80 million ...

The expansion will equip the Lexington site with an additional 24,000 square feet of manufacturing space, a new lab, and ...

Piramal Pharma’s stock price rose 2% in the opening trading on September 30 after the business received an Establishment ...

As the efficiency and efficacy of injectable treatment options improve, more patients are expected to benefit from advanced therapies.

In July 2024, the USFDA inspected the said facility with Zero Form - 483 observations and No Action Indicated (NAI) ...

Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma has unveiled an $80M investment plan to expand its Lexington, ...

Piramal Pharma aims to achieve $2 billion in annual revenue with a 25% operating margin by fiscal 2030, driven by its CDMO ...

Nandini Piramal has earned an MBA from Stanford University Graduate School of Business, California. She also holds a Bachelor ...